v3.26.1
Consolidated Statements of Shareholders' Equity - USD ($)
$ in Thousands
Total
Common Stock
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Balance at beginning of period (in shares) at Sep. 30, 2024   7,960,127    
Balance at beginning of period at Sep. 30, 2024 $ 245,413 $ 29,862 $ 215,531 $ 20
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 20,715   20,715  
Other comprehensive loss (795)     (795)
Repurchase of common stock (in shares)   (123,404)    
Repurchase of common stock, net of tax (3,846) $ (3,846)    
Restricted stock grant forfeitures (in shares)   (1,830)    
Restricted stock grant forfeitures $ (11) $ (11)    
Exercise of stock options (in shares) 41,960 41,960    
Exercise of stock options $ 817 $ 817    
Common stock dividends (6,033)   (6,033)  
Stock-based compensation expense 404 $ 404    
Balance at end of period (in shares) at Jun. 30, 2025   7,876,853    
Balance at end of period at Jun. 30, 2025 256,664 $ 27,226 230,213 (775)
Balance at beginning of period (in shares) at Mar. 31, 2025   7,903,489    
Balance at beginning of period at Mar. 31, 2025 252,524 $ 28,028 225,166 (670)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 7,100   7,100  
Other comprehensive loss (105)     (105)
Repurchase of common stock (in shares)   (34,236)    
Repurchase of common stock, net of tax (1,053) $ (1,053)    
Exercise of stock options (in shares)   7,600    
Exercise of stock options 130 $ 130    
Common stock dividends (2,053)   (2,053)  
Stock-based compensation expense 121 $ 121    
Balance at end of period (in shares) at Jun. 30, 2025   7,876,853    
Balance at end of period at Jun. 30, 2025 256,664 $ 27,226 230,213 (775)
Balance at beginning of period (in shares) at Sep. 30, 2025   7,889,571    
Balance at beginning of period at Sep. 30, 2025 262,614 [1] $ 26,305 236,607 (298)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 23,068   23,068  
Other comprehensive loss (869)     (869)
Repurchase of common stock (in shares)   (179,303)    
Repurchase of common stock, net of tax $ (6,968) $ (6,968)    
Restricted stock grant forfeitures (in shares)   (2,280)    
Exercise of stock options (in shares) 61,680 61,680    
Exercise of stock options $ 1,594 $ 1,594    
Common stock dividends (6,767)   (6,767)  
Stock-based compensation expense 534 $ 534    
Balance at end of period (in shares) at Jun. 30, 2026   7,769,668    
Balance at end of period at Jun. 30, 2026 273,206 $ 21,465 252,908 (1,167)
Balance at beginning of period (in shares) at Mar. 31, 2026   7,833,643    
Balance at beginning of period at Mar. 31, 2026 271,089 $ 23,982 247,457 (350)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Net income 7,720   7,720  
Other comprehensive loss (817)     (817)
Repurchase of common stock (in shares)   (70,000)    
Repurchase of common stock, net of tax (2,861) $ (2,861)    
Restricted stock grant forfeitures (in shares)   (200)    
Exercise of stock options (in shares)   6,225    
Exercise of stock options 155 $ 155    
Common stock dividends (2,269)   (2,269)  
Stock-based compensation expense 189 $ 189    
Balance at end of period (in shares) at Jun. 30, 2026   7,769,668    
Balance at end of period at Jun. 30, 2026 $ 273,206 $ 21,465 $ 252,908 $ (1,167)
[1] Derived from audited consolidated financial statements.